Clovis Oncology Inc (CLVS): Are Hedge Funds Right About This Stock?

Page 1 of 2

We can judge whether Clovis Oncology Inc (NASDAQ:CLVS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into their best ideas. While not all of these picks will be winners, research shows that these picks historically outperformed the market when we factor in known risk factors.

Is Clovis Oncology Inc (NASDAQ:CLVS) a good investment right now? Prominent investors are becoming more confident. The number of bullish hedge fund bets improved by 2 in recent months. At the end of this article we will also compare CLVS to other stocks including Rackspace Hosting, Inc. (NYSE:RAX), Blue Buffalo Pet Products Inc (NASDAQ:BUFF), and Healthsouth Corp. (NYSE:HLS) to get a better sense of its popularity.

Follow Clovis Oncology Inc. (NASDAQ:CLVS)

Keeping this in mind, we’re going to review the fresh action surrounding Clovis Oncology Inc (NASDAQ:CLVS).

What have hedge funds been doing with Clovis Oncology Inc (NASDAQ:CLVS)?

Heading into Q4, a total of 31 of the hedge funds tracked by Insider Monkey were long this stock, a change of 7% from one quarter earlier. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were boosting their stakes significantly (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, William Leland Edwards’s Palo Alto Investors has the largest position in Clovis Oncology Inc (NASDAQ:CLVS), worth close to $285.9 million, corresponding to 13.7% of its total 13F portfolio. On Palo Alto Investors’s heels is Partner Fund Management, managed by Christopher James, which holds a $234.8 million position; the fund has 6.6% of its 13F portfolio invested in the stock. Remaining peers that hold long positions consist of Eric Chen’s Antipodean Advisors, Samuel Isaly’s OrbiMed Advisors and Jeremy Green’s Redmile Group.

Page 1 of 2